
|Videos|July 21, 2022
Stephen Stripling, MD, FAAP, Discusses Study of Berdazimer Gel for Molluscum Contagiosum
Author(s)Kaitlyn Bader, Associate Editor
Results published in the Journal of the American Medical Association (JAMA) Dermatology detailed the efficacy and safety of berdazimer gel 10.3%, in the treatment of molluscum contagiosum.
Advertisement
With no current FDA-approved treatments for molluscum contagiosum, Stephen Stripling, MD, FAAP, and co-medical director at Coastal Pediatric Research in Charleston, South Carolina, explains the importance of the JAMA berdazimer gel 10.3% study1 and the hope it provides for patients and their families.
Reference:
- Browning JC, Enloe C, Cartwright M, et al. Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. Published online July 13, 2022. doi:10.1001/jamadermatol.2022.2721
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
4
Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing
5



















